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Hemorrhagic Fever Viruses
Viral hemorrhagic fevers (VHF) are a group of illnesses that are 
characterized by a loss of homeostasis leading to increased bleeding 
and shock. VHFs are caused by enveloped RNA viruses from four 
different families: Arenaviridae, Bunyaviridae, Filoviridae, and 
Flaviviridae [1]. The bleeding signs of VHF are more frequently 
associated with Marburg and Ebola (Filoviruses), Crimean Congo 
Hemorrhagic Fever (Bunyavirus), and South American hemorrhagic 
fever (Arenaviruses), but less frequently associated with Dengue and 
Yellow Fever (Flaviviruses), Rift Valley Fever (Bunyavirus) or Lassa 
fever (Arenavirus) [2]. A common characteristic of all hemorrhagic 
fever viruses is that they infect vascular endothelial cells and diminish 
platelet numbers or function. However, these viruses differ greatly in 
their replication strategies, extent of cytopathic effects, and extent of 
immunopathology [3]. Here, we review information on the effects of 
VHF on platelet functions, with emphasis on dengue hemorrhagic fever 
pathogenesis.
Biothreat of Viral Hemorrhagic Fevers (VHF)
VHFs have a number of properties that make them potential 
bioweapons, whereas the arenaviruses and filoviruses are aerosolizable; 
such high doses are needed for infection that they are unlikely to be 
transmitted that way. Outbreaks of VHF generally center on bleeding 
patients, as a source of nosocomial infection for health care personnel. 
Also, the effects of VHF can be sufficiently dramatic to instill terror in 
a civilian population. Even if many of these diseases can be medically 
managed, this often requires treatment in ICU units. Thus, even if 
only a small number of patients develop the disease, as a result of an 
attack the image of infected patients bleeding from several orifices, the 
risk of spread of infection from blood and the pressure placed on ICU 
resources would all serve to terrorize a civilian population. 
One of the biggest problems in dealing with a VHF outbreak due 
to a bioterrorist attack is the ability to identify the causative agent. 
Outbreaks occurring in their endemic regions are easier to identify 
than those occurring in new regions. Thus, a patient presenting with 
hemorrhagic fever in Malaysia is most likely to have dengue fever, 
while in Eastern Europe, it would be CCHF. Doctors are aware of these 
endemic diseases and look out for them in patients. If there were an 
imported case or a covert release of a VHF agent in a US city, it would 
take doctors a long time to appreciate that the patients had VHF, as they 
would not have any of the typical risk factors. Furthermore, it would be 
very difficult to identify the causative agent, as most VHFs have similar 
presentations. Even if there were anti-viral agents available, they would 
be unlikely to be effective against all agents, as the viruses are from 
different families. However, a common factor with all of these viruses 
is their ability to evade the innate immune system and compromise 
platelet function. Thus, platelets are a potential drug target in the 
treatment of VHFs. Therefore, the study of the role of platelets in the 
VHF pathogenesis may lead to the identification of new drug targets 
that will not only inhibit viral replication, but will also improve the 
antiviral immune response, preventing the onset of the hemorrhagic 
disease. While targeting the platelet may not inhibit viral replication, it 
may provide time for the immune system to clear the virus, and thereby, 
preventing the onset of hemorrhagic fever.
Flaviviridae
Epidemiology of flavivirus hemorrhagic fevers: Dengue fever 
(DF) is caused by Dengue virus (DENV), a positive-strand RNA virus 
with four recognized serotypes [4]. It is transmitted by the Aedes aegypti 
mosquito, and is endemic in Asia and South America, and is expanding 
to areas that were considered DENV free [5,6]. Worldwide, there are 
around 100 million infections per year, with case fatality rates between 
1-15% [7,8], depending on whether a person gets simple DF or the 
more severe Dengue hemorrhagic fever (DHF). Each DENV serotype 
is capable of inducing severe disease, but if a patient was infected 
with DENV serotype 1 and acquires serotype 2 or 3, there is a higher 
probability of developing hematopathology, characterized by a massive 
thrombocytopenia and disseminated intravascular coagulation (DIC). 
There are approximately 500,000 cases annually of severe DHF [7-10]. 
In some cases, this progresses to complete circulatory collapse, which is 
known as dengue shock syndrome (DSS) [9,11].
Yellow fever (YF) is another member of Flaviviridae (transmitted by 
mosquitos: Aedes albopictus, A. africanus, A. hemagogus or A. sabethes). 
YF is endemic in tropical and subtropical areas of South America and 
Africa, where it causes around 200,000 cases per year, with around 
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30,000 deaths [12]. After initial infection, there is an “acute” phase with 
flu-like symptoms that can be resolved in 3 or 4 days. However, 15% 
of YF patients enter a phase of intoxication, which is characterized by 
hepatic and renal failure and hemorrhage. Up to 30% of patients in the 
intoxication stage will die. Yellow fever hemorrhagic fever occurs just 
as antibodies appear in the circulation, suggesting a potential role for 
antibodies in the thrombocytopenia [13].
Other flaviviruses include Omsk hemorrhagic fever virus [14], and 
Kyanasur Forest virus [15], which are transmitted by ticks, and also 
cause hemorrhagic fever.
Biothreat of Dengue virus: Due to its significant public health 
impact, the absence of a vaccine, and a well-characterized pathogenesis, 
we will describe in more detail the known facts surrounding DHF.
Dengue virus structural features: All four of the DENV serotypes 
(DENV-1, 2, 3 and 4) are believed to arise from a common ancestor, 
and homology between the viruses can be as low as 60%, and diversity 
is further enhanced by the existence of a number of genotypes within 
each serotype [16]. The mature virus is a 50 nm diameter sphere, 
consisting of a central electron dense core surrounded by a lipid bilayer 
and an external, icosahedral protein scaffold [17]. The core contains 
the 11 kb RNA genome encapsulated by multiple 11 kDa capsid (C) 
proteins, while the protein scaffold consists of 180 copies each of a 53 
kDa envelope (E) protein, and an approximately 8 kDa membrane (M) 
protein; both of which are anchored in the lipid bilayer. In the mature 
virus, the membrane protein lies completely beneath the envelope 
protein [17].
Dengue virus replication: The virus enters host cells by receptor-
mediated endocytosis [18,19], where low-pH conditions in the 
endosome induce uncoating of the viral genome, followed by translation 
and replication of the virus [20,21]. The genomic RNA is translated as 
a single polyprotein, which is co- and post- translationally processed 
by virus encoded and host proteases, into the 3 structural (envelope 
(E), pre-membrane (prM) and capsid proteins), and 7 non-structural 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins [22,23]. The 
non-structural proteins initiate the replication of the viral genome, in 
close association with the endoplasmic reticulum (ER), and the newly 
synthesized RNA is packaged by the C protein, forming a nucleocapsid 
complex. The nucleocapsids bud from the ER and become enveloped by 
a lipid membrane, carrying with it associated E and the prM proteins. 
These form prM/E heterodimers that subsequently associate into trimers 
[17,23], which on the newly formed immature virus project from the 
surface as 60 trimeric spikes, with a diameter of approximately 600 
Angstroms [24,25]. After budding from the ER, the immature viruses 
transit the secretory pathway, where the prM protein is cleaved by the 
cellular furin protease, after a major conformational change induced 
by the acidic environment of the trans-Golgi environment [24,25]. The 
cleaved “pr” domain of the prM protein remains in association with 
the essentially mature virus particle, preventing premature membrane 
fusion inside the cell, until exposure to a neutral pH in the extracellular 
milieu induces dissociation of the “pr” peptide in the final step of virion 
maturation [25]. Due to inefficient furin cleavage, as much as 30% 
of virions released are immature virions [19]. While these immature 
virions are not infectious, they do bind to Fc bearing cells in the 
presence of anti-prM antibodies [26].
Expression of the prM and E proteins (in the absence of the capsid 
protein) leads to the formation of slightly smaller coreless particles 
[27]. These recombinant subviral particles (RSPs) are similar in 
immunogenicity to native virions [28], and as such represent an easily 
manipulable system, as mutation of the furin cleavage site can generate 
either predominantly “mature” or “immature” RSPs [29]. These RSPs, 
therefore, represent an ideal tool to investigate the interaction of the 
dengue E or prM/E proteins with cells in a non-infectious system.
While the majority of the non-structural proteins are solely 
intracellular during infection, there is one notable exception, the 50 kDa 
NS1 protein. Numerous studies have shown that the NS1 glycoprotein 
is exported through the secretory pathway to the cell surface, and that 
it can dissociate from the plasma membrane and accumulate in the 
extracellular medium as a hexamer [30]. In vivo, high levels of NS1 
are found in the sera of dengue infected patients, where it may have 
an immuno-modulatory role through its binding to the complement 
regulatory factor H [31].
Dengue clinical characteristics: Dengue has a wide spectrum 
of clinical presentations. While most patients recover following a 
self-limiting non-severe clinical course, a small proportion progress 
to severe disease, characterized by plasma leakage, with or without 
hemorrhage. Symptomatic DENV infections are grouped into three 
categories: undifferentiated fever, DF and DHF. DHF is further classified 
into four severity grades, with grades III and IV being defined as DSS 
[8]. Infection with any of the four serotypes causes a similar clinical 
course that may vary in severity, depending on a number of risk factors. 
Important risk factors influencing the proportion of patients who have 
severe disease during epidemic transmission include the serotype of 
the infecting virus and the immune status, age, previous exposure to 
different serotypes and genetic background of the patient [32].
Manifestations of DF depend on the age of the patient. Infants and 
children younger than 15-years may have an undifferentiated febrile 
disease, accompanied by a maculopapular rash. After an incubation 
period of 4 to 7 days, older children and adults will seek treatment with 
either a mild febrile illness or an incapacitating disease, characterized 
by the rapid onset of high fever, in combination with severe headache, 
retro-ocular pain, muscle and joint pain, rash, nausea and vomiting, 
diarrhea, abdominal pain, malaise and lymphadenopathy. Mild signs 
of pistaxis, petechiae, gingival bleeding, hematuria and menorrhagia 
are common. Leukopenia (commonly caused by a neutropenia) and 
lymphocytosis are usually seen (atypical lymphocytes), and a moderate 
thrombocytopenia may be observed in DF, especially in those with 
hemorrhagic signs [33,34].
DHF is primarily a disease of children under the age of 15 years, 
although it may also occur in adults. It has sudden onset of fever, and 
a variety of non-specific signs. The major pathophysiologic hallmarks 
that determine disease severity and distinguish DHF from DF are (i) 
hemorrhagic manifestations (positive tourniquet test or spontaneous 
bleeding), (ii) increased vascular permeability, resulting in loss of 
plasma from the vascular compartment, leading to hemoconcentration 
or fluid effusion in chest or abdominal cavities and shock, and (iii) a 
disorder of homeostasis involving vascular changes, thrombocytopenia, 
and coagulopathy. Towards the end of febrile phase, total leukocytes 
and neutrophils are reduced, just prior to an increase in both typical 
and atypical lymphocytes [32,35]. The liver is usually palpable early in 
the febrile phase, with mildly elevated liver enzymes [36], and clotting 
factor abnormalities [37-39]. Pleural effusion and ascites may also be 
detected, and may predict the development of DSS. Intense abdominal 
pain is a frequent complaint that appears shortly before the onset of 
shock.
The critical stage of the disease is reached at the end of the febrile 
phase, accompanying or shortly after rapid drop in temperature, 
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with varying degrees of circulatory disturbance [8,32]. The patient 
is often in a sweat, restless with cool extremities. In mild DHF cases 
(WHO grades I and II), the changes in vital signs are minimal and 
transient. Patients recover spontaneously or shortly after a brief period 
of treatment. The life-threatening DSS stage occurs at the time of or 
shortly after defervescence, which is characterized by a rapid, weak 
pulse with narrow pulse pressure or hypotension, and evidence of the 
early stage of shock (grade III). Although the course of shock is short, it 
is life-threatening for the patients. If patients do not receive prompt and 
appropriate treatment, a stage of profound shock may set in, in which 
pulse and blood pressure become undetectable (grade IV), resulting in 
death within 12 to 36 h after onset [8,32]. Prognosis depends on early 
recognition of DSS cases and adequate treatment of shock. Uncorrected 
shock will result in development of metabolic acidosis, severe bleeding 
from the gastrointestinal tract and other organs. Recovery from 
adequately treated DSS is short and uneventful, occurring within 2 
to 5 days, although pleural effusions and ascites may be detected for a 
little longer. The course of DHF/DSS is approximately 7 to 10 days, and 
usually shows no prolonged sequelae [32,37].
Dengue pathogenesis: Little is known about the pathogenesis 
of DHF or DSS. It is assumed that antibodies generated during the 
first exposure enhance infection with the second serotype [40-42], 
but as this occurs with other viral infections, it does not explain why 
hemorrhagic fever is not seen with other infections. The presence of 
antibodies to DENV enhances replication, rather than inhibiting it in 
a process known as antibody-dependent enhancement (ADE) [42,43]. 
This occurs through an interaction with Fc receptors [26,42,44,45], 
although it can also involve other receptors [46]. This process has also 
been shown to be regulated by complement generation [47,48], and to 
alter free radical and cytokine production [49].
Role of genetics in dengue fever pathogenesis: Epidemiological 
studies have shown that particular ethnic groups have increased 
tendency to developing severe DF. Past outbreaks of DHF and DSS 
in Cuba have implicated ethnicity as a strong predictor of disease 
severity. Epidemiological studies from outbreaks in 1981, 1997 and 
2001 have all consistently shown individuals of European ancestry to 
be over-represented, in terms of morbidity and mortality compared 
to individuals of African ancestry [50,51]. Strikingly, the same studies 
showed individuals of mixed African/European descent to carry an 
intermediate risk. A recent study of Dengue in Brazilian populations, 
showed Afro-Brazilian and African ancestry (determined genetically 
through ancestry informative markers, and after controlling for 
income), as protective for DHF [52]. In Asia, there have been reports of 
higher incidences of DHF among Han Chinese compared to Malaysians 
[53,54]. These reports all suggest that populations indigenous to 
Dengue regions have developed a degree of immunity to DHF/DSS, 
and this immunity may have a genetic basis.
Numerous studies have been reported in the literature, seeking to 
identify host genetic predictors of Dengue severity. All have followed 
a candidate gene design, focusing principally on the HLA and various 
other immune related genes (for summary of studies see [55]). However, 
none have identified consistent, reproducible genetic predictors of 
disease outcome. 
Filoviridae
The most severe VHF is caused by the Filoviruses, Marburg and 
Ebola. Marburg was discovered after an outbreak in laboratory workers 
in Marburg, Germany in 1967, and the Ebola virus was first identified 
in an outbreak in Democratic Republic of the Congo in 1976. They are 
thought to be carried by fruit bats in the endemic area of central Africa. 
Both are of interest as biological warfare agents due to their high case 
fatality (up to 90%) [56]. Both have a similar clinical presentation with 
an incubation period of around 6-days, followed by a flu-like syndrome, 
often accompanied by vomiting, diarrhea and abdominal pain. Over 
the following week, the patient deteriorates developing hypotension, 
bruising, bleeding and evidence of hemorrhagic shock. After 10 days, 
some patients begin to show signs of recovery, while the remaining 
patients eventually lapse into coma and die. A high virus titer is a 
predictor of poor outcome [57].
There is very little data on the nature of the Ebola hemorrhagic fever 
in humans, and much of the information comes from animal studies. 
Platelet activation was found in Ebola infected rhesus monkeys [58,59]. 
A common finding is a significant immune suppression, despite the 
presence of high levels of antigen. This manifests as severe suppression 
of the adaptive immune system, including a failure of antigen presenting 
cells to respond, extensive apoptosis of lymphocytes, and the generation 
of high levels of cytokines [60]. High levels of IFN have been associated 
with alteration in megakaryocyte development and platelet production 
in other VHF [61]. In patients infected with Ebola, there is a markedly 
increase in interferon (IFN)-gamma, IFN-α, IL-2, IL-10, and TNF-α, 
that could contribute not only to a high immune activation, but also to 
megakaryocyte malfunction [62].
Bunyaviridae
This family of RNA viruses is associated with a number of 
hemorrhagic fevers. In particular, Phleboviruses, such as Rift Valley 
fever virus, Nairoviruses like Crimean-Congo Hemorrhagic fever and 
Hantaan virus from the Hantavirus genus. 
Crimean-Congo Hemorrhagic fever: Crimean-Congo Hemorrhagic 
fever (CCHF) is a tick-borne zoonosis first described in 12th century 
Tajikistan, but not identified as a virus until it emerged in the Crimea in 
1944, and was subsequently shown to be the same virus that caused a disease 
outbreak in the Congo in animals in 1956 [63]. Humans can be exposed 
to the virus through the bite of an infected tick, contact with an infected 
patient, or infected livestock. CCHF can have a case fatality rate as high 
as 50%. The incubation period for CCHF is around 1 week, and then the 
patient enters the first phase, characterised by non-specific symptoms such 
as fever, headache, and muscle aches. During this phase, the platelet count 
begins to fall, the liver enzyme levels begin to rise, and viral load declines. 
By week 2, severe cases can enter into a second phase, which is associated 
with disseminated intravascular coagulation (DIC), with accompanying 
hemorrhage. Within 2-3 days, the patient either dies or recovers. The 
extent of thrombocytopenia is a good predictor of outcome in infected 
patients [64,65]. The CCHF virus has three genomic RNA segments (L, 
M and S). The segment L encodes the RNA polymerase. Recent structural 
studies show that CCHFV (bunyavirus) and Lassa virus (arenavirus) 
nucleocapsid proteins are more similar than N proteins of CCHFV and 
other bunyaviruses [66].
Other bunyavirus hemorrhagic fevers: Other significant members 
of the Bunyaviridae associated with hemorrhagic disease are members 
of Hantavirus and phleboviruses, such as Rift Valley fever virus [67]. 
Hantaan virus produces a hemorrhagic fever renal syndrome (HFRS), 
with around 100,000 cases each year and 3,000 deaths in China 
alone, and other Hantaviruses cause pulmonary syndromes in the 
Americas [68]. Thrombocytopenia is a common clinical finding in 
infections caused by bunyaviruses, and direct binding to platelets was 
demonstrated with the phlebovirus SFTS virus [69].
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Arenaviridae
The arenaviruses including Old World Lassa fever virus and the 
New World arenaviruses Junin, Guanarito, Machupo and Sabia are also 
capable of causing hemorrhagic fever [70]. They are carried by a variety 
of rodent species, and the infection is usually acquired through close 
contact with excrement or urine from infected animals. Although 80% 
of the infections are asymptomatic, some cases (for example during 
pregnancy, during nosocomial exposure, or after transplantation with 
infected blood) evolve into a more severe syndrome, with hepatic and 
pulmonary complications and hemorrhage. In West Africa, Lassa fever 
virus is responsible for about 300,000 cases per year with 5,000 deaths. 
Interestingly, platelet numbers during Lassa fever disease can be within 
the normal range, but arenaviral infection appear to induce a soluble 
factor that inhibits platelet aggregation [71,72]. Soluble P-selectin 
serum levels increase during arenavirus infection of mice, indicating 
that platelets can be activated during infection [73]. In vitro culture of 
human hematopoietic progenitors with Junin virus induces IFNα/ß, 
which causes the release of P-selectin from platelet granules [74]. Thus 
arenaviruses can indirectly have negative effects on platelet function 
and production.
Role of Platelets in VHF Pathogenesis
Platelet biology 
Platelets are anucleate derivatives of megakaryocytes, and are the 
smallest and most numerous corpuscular component of blood [75]. 
The typical shape of resting platelets is discoid, and upon activation, 
they undergo a shape change to a globular form with pseudopodia. 
As platelets lack nuclei, their ability to synthesize proteins is limited, 
although they can translate stable megakaryocyte mRNA [76]. Platelets 
contain granules (α-granules, dense granules and lysosomes) for storage 
of important bioactive molecules, such as ADP, serotonin, calcium, and 
proteins such as fibrinogen and von Willebrand factor [77]. 
Platelets play a crucial role in thrombus formation. First, single 
platelets bind to a site of damaged endothelium, where collagen in 
the underlying extracellular matrix has been exposed. Platelet surface 
receptors for collagen α2β1 and GPVI), fibrinogen (GPIIb/IIIa), and von 
Willebrand factor (GPIb/IX/V), help to bind platelets to the exposed 
endothelium, resulting in platelet activation [78]. Upon activation, 
GPIIb/IIIa undergoes a conformational change that allows it to bind 
soluble fibrinogen [79]. At the same time, cytoplasmic granule contents 
are released, triggering activation of other platelets that are then 
recruited into the growing thrombus, plugging the endothelial damage. 
There are two general pathways to platelet activation. The 
first is mediated by “weak agonists” such as low-dose ADP, and 
involves activation of phospholipase A2 releasing arachidonic acid 
to be converted to thromboxane A2 by cyclooxygenase (COX). The 
second pathway is activated by “strong agonists”, and is mediated by 
phospholipase C.
Recently there has been a growing awareness that platelets also 
play an important role in the innate immune system [80,81]. Platelet 
granules contain platelet microbicidal peptides (PMP) and proteins 
which act to sterilize the wound [82]. However, the ability to activate 
platelets has been exploited by some pathogens to promote colonization 
and avoidance of the host immune responses [83]. Thus, strains of S. 
aureus that are susceptible to PMPs in vitro, are less likely to cause 
endovascular infections in humans, and are more rapidly cleared from 
the bloodstream than bacteria that are PMP-resistant [84-86]. Similarly, 
in experimental endocarditis, S. aureus that is resistant to PMPs in vitro 
is more virulent [87]. 
Platelet function
The primary role of platelets is in hemostasis; this is achieved 
through three distinct properties of platelets. First, platelets have the 
ability to adhere to the site of injury (adhesion). Secondly, they become 
activated and clump together (aggregation), and also secrete the 
contents of their granules (secretion). Adhesion is usually the critical 
initial stage in the process and acts to anchor the thrombus to the site 
of injury, and trigger the signaling events that lead to aggregation of the 
activated platelets. Secretion is also a significant step in the process, as 
the granules contain many bioactive substances, such as ADP, which 
helps activate other platelets.
As platelets are in very high concentration in the blood and are 
the first responders to an injury, they play a major role in preventing 
infection. They do this by adhering to the pathogen and secreting anti-
microbial peptides and chemokines that attract immune cells.
Platelet pharmacology
Due to the significant role played by platelets in the pathogenesis 
of cardiovascular disease, there has been a lot of effort to develop 
anti-platelet agents. The first and most widely used anti-platelet agent 
is aspirin, which acts to inhibit cyclooxygenase, and thus, platelet 
activation by all weak agonists. The second class of anti-platelet agents 
is the P2Y12 antagonists, such as clopidogrel and prasugrel. P2Y12 is 
the ADP receptor on platelets, and is critical in the amplification of 
thrombosis by ADP secreted from activated platelets. The third class of 
anti-platelet agent is the GPIIb/IIIa antagonists (abciximab, eptifibatide 
and tirofiban), which prevent fibrinogen binding and thus aggregation, 
but do not effect platelet activation or secretion. These drugs all block 
platelet function by a range of different agonists, and are often used 
together. Thus, clopidogrel and aspirin are usually administered 
together, as are aspirin and GPIIb/IIIa antagonists. Combination 
therapy provides robust inhibition of platelet function, however; it is 
also associated with increased bleeding risk.
Platelets, hemorrhagic fever and sepsis
At first glance there is much in common between VHF, sepsis and 
systemic inflammatory response syndrome (SIRS). Cytokine storm, 
characterized by massive increases in cytokine levels, may be involved 
in all of these disorders. Platelet dysfunction is certainly associated 
with SIRS [88,89], and sepsis [90-94]. Thrombocytopenia can be due 
to platelet activation alone [91], and can be independent of thrombin 
generation [95]. However, the precise role played by platelets is unclear. It 
is also unclear whether the pathogens are acting only indirectly through 
platelet-activating cytokines, or whether their direct interactions with 
platelets have further affects on platelet trafficking or platelet functions.
Platelets play an important role in septic shock [81,90,96-
102]. Activation of platelets leads to degranulation and adhesion to 
leukocytes and endothelial cells. They have also been shown to bind 
to neutrophils, forming neutrophil traps [103]. As platelets contain 
many vasoactive substances, such as serotonin, platelet factor 4 and 
histamine, their degranulation can down-regulate platelet production 
[104], and disrupt endothelial function. This platelet-endothelial 
interaction is also important in the pathogenesis of shock [98,102,105-
108]. In sepsis, neutrophil binding to platelets leads to platelet 
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sequestration in the liver [93], and adhered platelets support neutrophil 
adhesion [109]. Endothelial cell infection can lead to activation and 
subsequent adhesion of platelets [110]. Thus, endothelial cell activation 
has been suggested to drive HIV-associated thrombocytopenia [111], 
and DENV-infected endothelial cells support platelet adhesion [112]. 
The presence of activated platelets or platelet-leucocyte aggregates 
has also been shown to lead to activation of the endothelium [113]. 
Preliminary evidence suggests that the use of aspirin, and/or 
clopidogrel, may reduce mortality in sepsis [114,115]. However, while 
anti-platelet agents preserve platelet numbers, they do so by inhibiting 
platelet function, which may exacerbate hemorrhagic complications in 
thrombocytopenic patients.
The homeostatic control of coagulation depends on thrombin 
balancing pro- and anti-coagulant forces, as well as pro- and anti-
fibrinolytic consequences. In most VHF infections, this balance is 
lost, triggering excessive and dysregulated thrombin generation in 
vivo, leading to disseminated intravascular coagulation (DIC) [116]. 
The predominant functional consequence of thrombin generation is 
influenced by the nature of the inciting agent. In bacterial infections, 
this is typically microvascular thrombosis leading to organ failure. In 
DHF, there is hyperfibrinolysis, where thrombin activation of protease 
activated receptors induces vascular hyper-permeability resulting in 
DSS. Linked to the hypothesis of the central role played by DENV-
platelet interactions (Figure 1), platelet activation would lead to 
exposure of anionic phospholipid surfaces that can catalyse thrombin 
generation by 250,000 fold [117]. These surfaces also assemble and 
catalyse fibrinolytic reactions and secrete plasmin [118], the major 
fibrinolytic enzyme that lyses fibrin clot. Platelet-bound plasmin is 
also resistant to inhibition, and high plasmin levels can in turn induce 
platelet dysfunction, whilst also interfering with fibrinogen interactions 
with GPIIb/IIIa [118].
Virus-mediated platelet activation can happen through direct 
interaction with platelets, or indirect interactions. In the case of a 
direct interaction, this can be due to virus directly binding to platelets 
(Figure 1), or can be mediated by a plasma protein that binds to the 
virus, that can in turn bind to the platelet. Indirect activation of platelets 
can occur through a number of different mechanisms. Viruses can 
activate neutrophils, which then bind to platelets, clearing them from 
the circulation (Table 1). Alternatively, virus can activate the immune 
system leading to increased levels of circulating cytokines, which 
could play a role in activating platelets (Table 1). Direct virus binding 
to platelets could affect platelet function in coagulation and innate 
immune recognition (Table 1). Finally, infection of megakaryocytes 
could lead to reduced platelet production (Table 1).
Although for years, little was known about the interaction between 
platelets and viruses, recently there is an increased interest on this issue. 
Not only do hemorrhagic fever viruses subvert platelet production 
and hemostatic function, they are also able to subvert the platelet’s 
immunological role in pathogen recognition and control. Viruses are 
not unique in their ability to interact with platelets and experience with 
other pathogens that interact with platelets can provide some insight 
into the potential viral interactions.
Platelet activation by direct interactions with microbes: There 
is abundant evidence of platelet activation induced by bacteria 
through a direct interaction mechanism, resulting in thrombosis, 
and/or thrombocytopenia [119]. Thrombosis probably occurs when 
platelets and pathogen interact in a localized environment. Such is the 
case with infective endocarditis, where a bacteria-platelet thrombus 
occurs on the surface of a damaged cardiac valve. However, in the 
case of disseminated intravascular coagulation (DIC), the platelet 
activation occurs throughout the circulation. This results in clearance 
of the activated platelets. We have previously shown that Streptococcus 
sanguinis interacts with platelet GPIbα via HSA on its surface 
[120]. This interaction is sufficient to induce platelet activation and 
aggregation. Many bacteria bind a plasma protein, and then interact 
with platelets. We have previously shown that clumping factor A (Clf 
A) [121,122], and fibronectin-binding protein (FnBP) [123], induce 
platelet aggregation by binding either fibrinogen or fibronectin, which 
in turn, interacts with GPIIb/IIIa and Helicobacter pylori binds von 
Willebrand factor, which in turn interacts with GPIbα on the platelet 
surface [124]. Complement assembly on the bacterial surface interacts 
with a complement receptor on the platelet surface, leading to platelet 
activation [125-127].
Much less is known about the interaction of viruses with platelets, 
although a number of receptors known to be present on platelets have 
been shown to bind to different viruses. These include β3 integrins 
(Hantavirus [128]), α5β1 (Adenovirus [129]), Clec-2 (HIV [130]), 
α2β1 (Rotavirus [131]), and DC-SIGN (HIV [130], DENV [132], 
arenaviruses [133], Ebola virus [134,135], and Lentiviruses [136]). Axl 
and Tyro3 are Ebola virus [135, 137], and LASV receptors [133]. Ebola 
virus requires the cholesterol transporter Niemann-Pick C1 (NPC1) for 
cell entry [138] [Figure 1].
Platelet activation by indirect interactions with microbes: 
Indirect platelet-virus interactions have not been widely described so 
far. However, there is evidence of pathogens that can indirectly activate 
platelets, primarily through their interaction with immune cells. One 
example of this is seen with lipopolysaccharide (LPS) from Gram-
negative bacteria. LPS can stimulate platelet activation; however, it 
would appear that this is primarily due to activation of neutrophils, 
and subsequent platelet binding [103]. The other possibility is that 
activation of the immune system leads to increased cytokine levels, 
which may activate platelets. Certainly platelet dysfunction is also 
associated with SIRS [88,89]. Hemorrhagic fever viruses not only 
interact with platelets, but can also infect megakaryocytes. This is the 
case for some strains of Hantavirus associated with hemorrhagic fever, 
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Figure 1: There are different molecules and cellular receptors that can interact 
with HFV such as Hantavirus. Although they are present in platelets the direct 
interaction between them and these viruses has not been demonstrated. These 
possible interactions are represented in italic font.
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by T-cells [139]. Similarly, cytomegalovirus infection of megakaryocytes 
triggers caspase-mediated apoptosis resulting in thrombocytopenia 
[140]. Recent studies suggest that DENV also infects megakaryocytes, 
and inhibits megakaryopoiesis by inducing apoptosis in vitro [141,142].
Platelet FcγRIIa: The role of platelets in DHF/DSS is unclear. 
Certainly a severe thrombocytopenia occurs and is implicated in poor 
prognosis, however, is this secondary to DHF/DSS, or is it a key player 
in the pathogenesis? Anti-platelet antibodies or platelet-associated 
antibodies have been detected in some patients [108,111,143-145], 
and this may be due to molecular mimicry between a platelet antigen 
and a DENV antigen [144], and molecular mimicry is known to occur 
with other microorganisms [146-148]. However, this does not explain 
why a repeat infection is required for thrombocytopenia, as the platelet 
antigen should drive the immune response. One possible explanation 
is that anti-viral antibodies cross-react with an activation-dependent 
antigen. This is not unusual, and is the mechanism involved in heparin-
induced thrombocytopenia [98]. Heparin mildly activates platelets, 
causing them to express platelet factor 4 (PF4) on their surface, 
which is not found on the surface of a resting platelet. Antibodies 
are directed against the PF4-heparin complex on the platelet surface, 
thereby bringing them into contact with platelet FcγRIIa. Thus, virus 
may partially activate platelets, causing increased binding to FcγRIIa, 
and generating thrombocytopenia. In the absence of virus, there is no 
platelet activation, and no thrombocytopenia. There is some evidence 
to suggest that this may be the case, as it has previously been shown 
that DENV is capable of binding to platelets, and that antibody can 
exacerbate the subsequent thrombocytopenia [108].
Another possibility is the role of antibody-dependent enhancement 
[43]. This describes a process where non-neutralizing anti-Dengue 
antibodies [40,149] bind to the virus particle, and can interact with 
Fc receptors on cells aiding the infection process, a process that can 
also involve complement generation [47,150]. This is a process that is 
mechanistically similar to bacterial-induced platelet activation [119], 
where bacteria-bound, non-neutralizing antibodies can interact with 
platelet FcγRIIa receptor [123,125,126,151,152]. We have shown that 
complement plays a role in platelet activation as well [125-127]. Several 
publications point to similar pathogen-platelet interactions, with 
regard to Dengue virus. Wang et al. [153] showed that antibody-bound 
DENV-2 virus can bind to platelets, and was not inhibited by the anti-
FcγRIIa antibody IV.3. This, however, is not unusual as IV.3 inhibits S. 
sanguinis-induced platelet aggregation, but not S. sanguinis mediated 
adhesion to platelets [152]. The reason for this is that the interaction 
with FcγRIIa is a weak interaction and cannot support adhesion, which 
is usually mediated by a specific adhesion molecule. With bacteria, at 
least, the effect of the FcγRIIa interaction is to trigger platelet activation 
and usually that occurs in the presence of a secondary adhesive 
interaction [119]. While these studies suggest that a direct virus-platelet 
interaction may take place, and that this can be enhanced by antibody, 
neither the platelet nor virus antigens involved have been identified nor 
has the role for antibody been clarified.
Targeting the platelet in VHF
While vaccination is potentially beneficial in preventing people 
from developing VHF, as shown by YF17D and Candid#1 vaccination, 
there are no approved vaccines for other VHF. Thus, treating the patient 
with VHF is the only possible option at present. There are two potential 
strategies for treating VHF. The first is to inhibit viral replication, and the 
second is to inhibit the host response to infection. Currently, no drugs 
have been approved to inhibit viral replication in VHF. However, there 
is some evidence to suggest that ribavirin may be beneficial in some 
types of VHF, although its mechanism of action is unknown [154,67]. 
The second approach is to prevent development of the hemorrhagic 
fever. This could potentially be achieved with conventional anti-platelet 
agents. For instance, there is evidence that aspirin may be beneficial in 
sepsis [155,156], and other critically ill patients associated with SIRS 
[115], and this is also true for clopidogrel [157]. There is a paucity of 
studies of the use of anti-platelet agents in VHF, although a 1979 paper 
found that while the combination of aspirin and dipyridamole did not 
affect mortality, it did reduce the progression to DHF [158].
The biggest concern with using conventional anti-platelet agents 
is that they preserve platelet number, but at the expense of inhibiting 
platelet function. In the case of patients with hemorrhagic fever, this 
may increase the risk of bleeding. To make matters worse, many are 
irreversible inhibitors, and thus, if the patient develops a bleeding 
problem, there is little that can be done. The obvious anti-platelet 
agent to use is a P2Y12 antagonist, as it is effective at inhibiting 
platelet activation by many different agents. Recently, reversible P2Y12 
antagonists, such as cangrelor have been developed [159]. While these 
agents will completely inhibit platelet function, their effects can be 
rapidly reversed in the case of bleeding complications.
A more effective strategy would be to prevent the interaction of the 
viruses with platelet in the first place. There are a relatively small number 
of receptors on the platelet surface that could interact with viruses, and 
most of these have been the subjects of drug discovery programmes 
[160]. While few have been approved, this is primarily due to the lack 
of a suitable indication, rather than failure to discover inhibitors. The 
dominant receptor is GPIIb/IIIa, the fibrinogen receptor, and there 
are already 3 approved inhibitors of this receptor [161]. The next most 
abundant receptor is GPIbα, the von Willebrand receptor, and inhibitors 
have been discovered and used in animal models of thrombosis [162]. 
Other receptors include the collagen receptors α2β1 and GPVI [163], 
and PAR-1, the thrombin receptor [164]. As discussed above, FcRIIa 
is an important receptor for the interaction of DENV with platelets, 
and small molecule inhibitors of this receptor have been discovered 
[165]. Selectively inhibiting the interaction of viruses with platelets 
has the advantage of preventing virus-mediated platelet activation and 
subsequent thrombocytopenia, while preserving platelet function.
Conclusion
In conclusion, a detailed description of the hemorrhagic fever 







Inhibition of platelet 
functiond
Hantavirus [166] SFTS [69] Hantavirus [139] Hantavirus [166]
DENV [112,167,168] DENV [169] LASV [71]
JUNV [74,170] JUNV [72]
Ebola [62]
aDestruction of platelets by direct interaction: SomeHFV can bind platelets directly 
causing activation and granules release.
bImmunological destruction of platelet-virus complexes: Thrombocytopenia can be 
mediated by macrophages sequestration of platelet-virus complexes at the local 
site or/and in the spleen, platelets-virus-leukocyte aggregation and subsequent 
phagocytosis by macrophages or destruction mediated by platelet-virus associated 
antibodies.
dInhibition of platelet function: Some unidentified soluble factors present in plasma 
from infected patients can inhibit aggregation of platelets from healthy individuals.
Table 1: Four main mechanisms by which Haemorrhagic fever viruses (HFV) can 
induce thrombocytopenia.
cMegakaryocytes or Megakaryocyte precursors impairment: Some HFV can 
infect megakaryocytes or their precursor causing reduction in platelet number or 
impairment in their function. 
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virus-platelet interaction, and the role of platelets in VHF pathogenesis 
is important not only for unraveling the mysteries of this group of 
diseases, but also for developing therapies that prevent the appearance 
of hemorrhagic signs.
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